CTOs on the Move

Vigil Neuroscience

www.vigilneuro.com

 
Vigil Neuroscience is the world`s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain`s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vigilneuro.com
  • One Broadway Suite 07-300
    Cambridge, MA USA 02142
  • Phone: 857.254.4445

Executives

Name Title Contact Details

Funding

Vigil Neuroscience raised $50M on 12/08/2020

Similar Companies

Clene

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.

Rénibus Therapeutics

Rénibus Therapeutics® Inc. | A biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease.

Medico Labs Inc

Medico Labs Inc is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alpharma Integrated Solutions

Alpharma Integrated Solutions is a Vega Baja, PR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.